 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || cagrilintide (AM833) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date, Trial primary completion date: Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (clinicaltrials.gov) - Nov 26, 2024
P2, N=240, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Nov 2025
- | zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - Aug 22, 2024
P1, N=35, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Sep 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Nov 2025 Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
- | NN9500 / Novo Nordisk
Journal: Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog. (Pubmed Central) - Jul 26, 2024
Here, we describe the development of the FGF21 analog zalfermin (NNC0194-0499, 15), intended for once-weekly sc dosing...The fatty diacid binds albumin in a reversible manner, such that the free fraction of zalfermin potently activates the FGF-receptor complex and retains receptor selectivity compared with FGF21, providing strong efficacy on body weight loss in diet-induced obese mice. Zalfermin is currently being clinically evaluated for the treatment of metabolic dysfunction-associated steatohepatitis.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial primary completion date: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jun 11, 2024
P2, N=672, Active, not recruiting, Sponsor: Novo Nordisk A/S
Zalfermin is currently being clinically evaluated for the treatment of metabolic dysfunction-associated steatohepatitis. Trial primary completion date: May 2024 --> Oct 2024
- |||| cagrilintide (AM833) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (clinicaltrials.gov) - May 28, 2024
P2, N=240, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: May 2024 --> Oct 2024 Not yet recruiting --> Recruiting
- ||||| cagrilintide (AM833) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
New P2 trial: Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (clinicaltrials.gov) - May 9, 2024
P2, N=240, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - Feb 15, 2024
P1, N=35, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (clinicaltrials.gov) - Feb 15, 2024
P1, N=53, Completed, Sponsor: Novo Nordisk A/S
Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024 Recruiting --> Completed
- || zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children. (clinicaltrials.gov) - Jan 2, 2024
P1, N=30, Recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (clinicaltrials.gov) - Dec 21, 2023
P1, N=48, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Dec 15, 2023
P2, N=672, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024 Recruiting --> Active, not recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - Dec 6, 2023
P1, N=42, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - Dec 5, 2023
P1, N=42, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023 Recruiting --> Active, not recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - Jul 25, 2023
P1, N=35, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion, Trial completion date: A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men (clinicaltrials.gov) - Jun 28, 2023
P1, N=24, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023
- || zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - Jun 26, 2023
P1, N=35, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men (clinicaltrials.gov) - Mar 31, 2023
P1, N=24, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023 Not yet recruiting --> Recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - Mar 31, 2023
P1, N=42, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (clinicaltrials.gov) - Mar 30, 2023
P1, N=48, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations (clinicaltrials.gov) - Mar 13, 2023
P1, N=48, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men (clinicaltrials.gov) - Feb 24, 2023
P1, N=24, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - Feb 14, 2023
P1, N=42, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion date: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Nov 14, 2022
P2, N=672, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial completion date: Sep 2024 --> Dec 2024
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Sep 7, 2021
P2, N=672, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Sep 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, zalfermin (NNC0194-0499) / Novo Nordisk
New P2 trial: Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Aug 22, 2021
P2, N=672, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion: A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men (clinicaltrials.gov) - Apr 29, 2021
P1, N=42, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men (clinicaltrials.gov) - Apr 13, 2021
P1, N=42, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men (clinicaltrials.gov) - Feb 28, 2021
P1, N=42, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men (clinicaltrials.gov) - Jan 25, 2021
P1, N=42, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion: A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity (clinicaltrials.gov) - Jun 24, 2019
P1, N=57, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity (clinicaltrials.gov) - May 10, 2019
P1, N=57, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity (clinicaltrials.gov) - Mar 27, 2018
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
- ||| zalfermin (NNC0194-0499) / Novo Nordisk
Trial completion: First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (clinicaltrials.gov) - Oct 30, 2017
P1, N=56, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment closed: First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (clinicaltrials.gov) - Sep 27, 2017
P1, N=56, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| zalfermin (NNC0194-0499) / Novo Nordisk
Enrollment open: First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (clinicaltrials.gov) - Feb 7, 2017
P1, N=56, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| zalfermin (NNC0194-0499) / Novo Nordisk
New P1 trial: First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (clinicaltrials.gov) - Jan 8, 2017
P1, N=56, Not yet recruiting, Sponsor: Novo Nordisk A/S